Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Cipla to buy Meditab for $28m

25-Aug-2010

Related topics: Excipients, raw materials and intermediates, Ingredients, Globalisation, Mergers and acquisitions

Indian pharmaceutical firm Cipla is to buy Meditab Specialties to boost active pharmaceutical ingredient (API) and intermediate production capacity.

The deal, worth INR1.33bn ($28.3m) according to reports in the Indian press, is being undertaken to facilitate Cipla’s entry into the Chinese, African and Malaysian pharmaceutical markets where Meditab has manufacturing and formulation facilities.

The news follows just days after reports of Cipla’s efforts to find a Big Pharma partner to help it access the $3bn a year choloroflurocarbon (CFC) free inhaler.

The Financial Express suggested that the India drugmaker is in early stage talks with GlaxoSmithKline, Pfizer and Goehringer Ingelheim about a potential deal.

Cipla has not yet issued a statement.

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.